Oncotelic Accesses Rapid IND Development Platform through Partnership with Medicilon
Oncotelic Therapeutics (OTCQB:OTLC), a leader in RNA-based therapeutics, has announced a strategic partnership with Shanghai Medicilon (688202.SH) to accelerate its drug development pipeline. Through this collaboration, Oncotelic and its subsidiary SAPU Bioscience will utilize Medicilon's rapid IND development platform to support up to 20 Investigational New Drug projects.
Currently, six INDs are already ongoing, focusing on next-generation anticancer agents. This partnership will leverage Medicilon's integrated platform for drug discovery, pharmaceutical research, and preclinical development to expedite regulatory pathways for upcoming submissions.
Dr. Vuong Trieu, Chairman and CEO of Oncotelic and SAPU, described the partnership as a "game-changer" for their development programs. Dr. Chen Chunlin, Founder and CEO of Medicilon, emphasized their organization's comprehensive services from early discovery to IND registration, designed to accelerate the translation of Oncotelic and SAPU's pipeline into new therapeutic options for patients.
Oncotelic Therapeutics (OTCQB:OTLC), un leader nelle terapie basate su RNA, ha annunciato una partnership strategica con Shanghai Medicilon (688202.SH) per accelerare il suo pipeline di sviluppo farmaceutico. Attraverso questa collaborazione, Oncotelic e la sua sussidiaria SAPU Bioscience utilizzeranno la piattaforma di sviluppo rapido IND di Medicilon per supportare fino a 20 progetti di Nuovo Farmaco Sperimentale.
Attualmente, sei IND sono già in corso, concentrandosi su agenti anticancro di nuova generazione. Questa partnership sfrutterà la piattaforma integrata di Medicilon per la scoperta di farmaci, la ricerca farmaceutica e lo sviluppo preclinico, al fine di accelerare i percorsi regolatori per le prossime presentazioni.
Il Dr. Vuong Trieu, Presidente e CEO di Oncotelic e SAPU, ha descritto la partnership come un
Oncotelic Therapeutics (OTCQB:OTLC), un líder en terapias basadas en ARN, ha anunciado una asociación estratégica con Shanghai Medicilon (688202.SH) para acelerar su pipeline de desarrollo de medicamentos. A través de esta colaboración, Oncotelic y su subsidiaria SAPU Bioscience utilizarán la plataforma de desarrollo rápido de IND de Medicilon para apoyar hasta 20 proyectos de Nuevo Medicamento en Investigación.
Actualmente, seis IND ya están en curso, enfocándose en agentes anticancerígenos de nueva generación. Esta asociación aprovechará la plataforma integrada de Medicilon para el descubrimiento de medicamentos, la investigación farmacéutica y el desarrollo preclínico para acelerar los caminos regulatorios para las próximas presentaciones.
El Dr. Vuong Trieu, Presidente y CEO de Oncotelic y SAPU, describió la asociación como un
온코텔릭 테라퓨틱스 (OTCQB:OTLC)는 RNA 기반 치료제의 선두주자로서 상하이 메디시론 (688202.SH)과의 전략적 파트너십을 발표하며 약물 개발 파이프라인을 가속화할 계획입니다. 이번 협력을 통해 온코텔릭과 그 자회사 SAPU 바이오사이언스는 메디시론의 신속한 IND 개발 플랫폼을 활용하여 최대 20개의 임상시험용 신약 프로젝트를 지원할 것입니다.
현재 6개의 IND가 이미 진행 중이며, 차세대 항암제에 초점을 맞추고 있습니다. 이 파트너십은 메디시론의 통합 플랫폼을 활용하여 약물 발견, 제약 연구 및 전임상 개발을 통해 향후 제출을 위한 규제 경로를 가속화할 것입니다.
온코텔릭과 SAPU의 회장 겸 CEO인 Vuong Trieu 박사는 이번 파트너십을 개발 프로그램의
Oncotelic Therapeutics (OTCQB:OTLC), un leader dans les thérapies basées sur l'ARN, a annoncé un partenariat stratégique avec Shanghai Medicilon (688202.SH) pour accélérer son pipeline de développement de médicaments. Grâce à cette collaboration, Oncotelic et sa filiale SAPU Bioscience utiliseront la plateforme de développement rapide d'IND de Medicilon pour soutenir jusqu'à 20 projets de Nouveau Médicament d'Investigation.
Actuellement, six INDs sont déjà en cours, axés sur des agents anticancéreux de nouvelle génération. Ce partenariat exploitera la plateforme intégrée de Medicilon pour la découverte de médicaments, la recherche pharmaceutique et le développement préclinique afin d'accélérer les voies réglementaires pour les prochaines soumissions.
Dr. Vuong Trieu, Président et CEO d'Oncotelic et SAPU, a décrit ce partenariat comme un
Oncotelic Therapeutics (OTCQB:OTLC), ein führendes Unternehmen im Bereich RNA-basierte Therapeutika, hat eine strategische Partnerschaft mit Shanghai Medicilon (688202.SH) angekündigt, um seine Arzneimittelentwicklungspipeline zu beschleunigen. Durch diese Zusammenarbeit werden Oncotelic und seine Tochtergesellschaft SAPU Bioscience die schnelle IND-Entwicklungsplattform von Medicilon nutzen, um bis zu 20 Projekte für Untersuchungsneue Arzneimittel zu unterstützen.
Derzeit laufen bereits sechs INDs, die sich auf neuartige Antikrebsmittel konzentrieren. Diese Partnerschaft wird die integrierte Plattform von Medicilon für Arzneimittelentdeckung, pharmazeutische Forschung und präklinische Entwicklung nutzen, um die regulatorischen Wege für bevorstehende Einreichungen zu beschleunigen.
Dr. Vuong Trieu, Vorsitzender und CEO von Oncotelic und SAPU, bezeichnete die Partnerschaft als einen
- Strategic partnership with Shanghai Medicilon to accelerate drug development
- Access to rapid IND development platform for up to 20 projects
- Six INDs already ongoing focused on next-generation anticancer agents
- Expedited regulatory pathway for upcoming IND submissions
- Strengthening position as a leader in novel cancer therapies
- 45% ownership stake in GMP Biotechnology indicates non-controlling interest
AGOURA HILLS, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC). Oncotelic Therapeutics Inc., a leader in RNA-based therapeutics, including its subsidiaries (“Oncotelic”) and including Sapu Bioscience, LLC (“SAPU”), a wholly owned subsidiary of GMP Biotechnology Limited in which Oncotelic is a
Oncotelic and SAPU's partnership with Medicilon is poised to significantly accelerate the development of our innovative oncology pipeline. This collaboration reflects our strategic move to strengthen our position as a leader in novel cancer therapies.
Enabling Rapid Growth: Medicilon’s integrated platform for drug discovery, pharmaceutical research, and preclinical development will expedite the regulatory pathways for Oncotelic’s and SAPU’s upcoming IND submissions.
Portfolio Expansion: This initiative will initially focus on the current six INDs but has the potential to extend up to 20 projects, reflecting the depth of Oncotelic’s and its affiliates’ R&D programs.
Dr. Vuong Trieu, Chairman and CEO of Oncotelic and SAPU, stated, “This partnership is poised to be a game-changer for our development programs. The ability to access a rapid IND-enabling platform is crucial for accelerating SAPU’s and Oncotelic’s development programs. We look forward to continued success working with Medicilon as we advance innovative anticancer agents to the clinic.”
Dr. Chen Chunlin, Founder and CEO of Medicilon, remarked, “We are excited to partner with Oncotelic and SAPU and contribute our international experience in drug R&D. We are a comprehensive, one-stop services organization, from early discovery to IND registration, built to accelerate the translation of Oncotelic and SAPU’s pipeline into new therapeutic options for patients.”
About Medicilon
Medicilon is a leading Contract Research Organization providing a one-stop, integrated research and development services to pharmaceutical enterprises and research institutions worldwide. With a global perspective, Medicilon’s platform covers essential stages of drug discovery, pharmaceutical research, and preclinical development, striving to streamline drug development under international regulatory standards.
Contact
marketing@medicilon.com
About Oncotelic
Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its
Oncotelic's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the success of the launch of a company with a DAO infrastructure, the success of the entity and the plans surrounding the pet and animal health, the ability for the Company to register the tokens of Pet2DAO, the actual filing of a registration statement and approval of the PDAO, or any other tokens that we may launch, as registrable securities with the SEC through a registration statement, the ability of the tokens to be tradable or any value such tokens may have if they become tradable.. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's annual report on Form 10-K filed with the SEC on April 12, 2024 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise.
Contact Information:
For Oncotelic Therapeutics, Inc.:
Investor Relations
ir@oncotelic.com
FAQ
What is the strategic partnership announced by Oncotelic Therapeutics (OTLC)?
How many IND projects will Oncotelic (OTLC) develop through the Medicilon partnership?
What benefits does the Medicilon partnership provide to Oncotelic (OTLC) investors?
What is SAPU Bioscience's relationship to Oncotelic Therapeutics (OTLC)?
How will the Medicilon partnership affect Oncotelic's (OTLC) oncology pipeline development?
